

**Summary of Consolidated Financial Results [IFRS]
for the Fiscal Year Ended March 31, 2026**

May 14, 2026

Listed company name : Sysmex Corporation
 Code : 6869
 Listed stock exchanges : Tokyo Stock Exchange
 URL : www.sysmex.co.jp/en
 Company representative : Iwane Matsui, President
 Contact : Takuro Minami, Executive Vice President of
 Corporate Business Administration
 Phone : 078(265)-0500
 Scheduled date for shareholders' meeting : June 26, 2026
 Scheduled date for dividend payment : June 29, 2026
 Scheduled date for filing of financial report : June 22, 2026
 Preparation of supplementary material for earnings : Yes
 Holding of earnings announcement : Yes

(Unit: Millions of Yen)

1. Results for the Fiscal Year Ended March 31, 2026

(1) Operating results

(% changes as compared with the previous fiscal year)

	Net Sales		Operating profit		Profit before tax		Profit	
Year ended Mar. 31, 2026	500,006	(1.7)%	51,831	(40.8)%	49,051	(38.1)%	35,374	(34.0)%
Year ended Mar. 31, 2025	508,643	10.2%	87,583	11.7%	79,221	6.2%	53,576	7.6%

	Profit attributable to owners of the parent		Total comprehensive income		Basic earnings per share (Yen)	Diluted earnings per share (Yen)
Year ended Mar. 31, 2026	35,457	(33.9)%	66,601	34.7%	56.89	56.89
Year ended Mar. 31, 2025	53,669	8.1%	49,434	(32.6)%	86.07	86.05

	Return on equity (%)	Profit before tax to total assets (%)	Operating profit to net sales (%)
Year ended Mar. 31, 2026	7.3	7.1	10.4
Year ended Mar. 31, 2025	12.0	12.3	17.2

Reference:

Share of loss on equity method: 1,364 million yen for the year ended March 31, 2026; 2,071 million yen for the year ended March 31, 2025.

(2) Financial condition

	Total assets	Total equity	Equity attributable to owners of the parent	Equity attributable to owners of the parent to total assets (%)	Equity attributable to owners of the parent per share (Yen)
As of Mar. 31, 2026	707,532	505,676	505,000	71.4	812.57
As of Mar. 31, 2025	665,268	464,534	463,776	69.7	743.71

(3) Cash flows

	Cash flows from operating activities	Cash flows from investing activities	Cash flows from financing activities	Cash and cash equivalents at the end of the term
Year ended Mar. 31, 2026	73,848	(51,472)	(37,659)	84,117
Year ended Mar. 31, 2025	88,246	(52,488)	(24,322)	89,570

2. Dividend

	Dividend per share					Total dividend payment (Millions of yen)	Dividend payout ratio (Consolidated) (%)	Dividend to equity attributable to owners of the parent (Consolidated) (%)
	First quarter (Yen)	Second quarter (Yen)	Third quarter (Yen)	Year-end (Yen)	Annual (Yen)			
Year ended Mar. 31, 2025	—	15.00	—	17.00	32.00	20,098	37.4	4.5
Year ended Mar. 31, 2026	—	19.00	—	19.00	38.00	23,836	67.3	4.9
Year ending Mar. 31, 2027 (Forecast)	—	20.00	—	20.00	40.00		69.6	

Notes:

- The total amount of cash dividends for the fiscal year ended March 31, 2025 includes 144 million yen of the dividends for the shares of the Company held by the Stock-Granting Employee Stock Ownership Plan (ESOP) Trust. The total amount of cash dividends for the fiscal year ended March 31, 2026 includes 188 million yen in dividends on Company shares held by the Executive Compensation BIP Trust and the ESOP Trust.
- Composition of the year-end dividend for the fiscal year ended March 31, 2026:
Second quarter; Ordinary dividend 18.00 yen per share and Commemorative dividend of 30 years anniversary of listing 1.00 yen per share.
Year-end; Ordinary dividend 18.00 yen per share and Commemorative dividend of 30 years anniversary of listing 1.00 yen per share.

3. Financial Forecast for the Year Ending March 31, 2027

(% changes as compared with the corresponding period of the previous fiscal year)

	Net Sales		Operating profit		Profit before tax		Profit attributable to owners of the parent		Basic earnings per share (Yen)
Six months ending Sep. 30, 2026	255,000	9.7%	23,000	(30.2)%	21,000	(29.9)%	14,000	(26.4)%	22.53
Year ending Mar. 31, 2027	535,000	7.0%	58,000	11.9%	54,000	10.1%	36,000	1.5%	57.93

4. Other Information

- Significant changes in scope of consolidation: No
- Changes in accounting policies and accounting estimates
 - Changes in accounting policies required by IFRS: No
 - Other changes in accounting policies: No
 - Changes in accounting estimates: No
- Number of outstanding stock (common stock)
 - Number of outstanding stock at the end of each fiscal period (including treasury stock):
629,480,076 shares as of Mar. 31, 2026; 629,473,176 shares as of Mar. 31, 2025
 - Number of treasury stock at the end of each fiscal period:
7,995,365 shares as of Mar. 31, 2026; 5,873,371 shares as of Mar. 31, 2025
 - Average number of outstanding stock for each period (cumulative):
623,213,959 shares for the year ended Mar. 31, 2026
623,531,760 shares for the year ended Mar. 31, 2025

Note: The Company has introduced the Executive Compensation BIP Trust and the ESOP Trust. Company shares held by these trusts are included in treasury stock and are excluded from calculations of the number of treasury stock at the end of the fiscal period and the average number of outstanding stock for the period.

(Reference) Summary of the Non-consolidated Financial Results for the Year Ended March 31, 2026**(1) Non-consolidated operating results**

(% changes as compared with the previous fiscal year)

	Net Sales		Operating income		Ordinary income		Net income	
Year ended Mar. 31, 2026	197,359	(16.6) %	20,730	(63.2) %	41,041	(37.4) %	28,029	11.1 %
Year ended Mar. 31, 2025	236,780	7.0%	56,289	8.9%	65,598	(0.6)%	25,219	(26.5)%

	Net income per share (Yen)	Diluted net income per share (Yen)
Year ended Mar. 31, 2026	44.98	44.98
Year ended Mar. 31, 2025	40.45	40.43

(2) Non-consolidated financial condition

	Total assets	Net assets	Equity ratio (%)	Net assets per share (Yen)
As of Mar. 31, 2026	352,561	278,685	78.8	446.87
As of Mar. 31, 2025	364,655	275,148	75.2	439.55

Reference: Equity capital: 277,725 million yen as of March 31, 2026; 274,105 million yen as of March 31, 2025.

Note: Summaries of financial results are not subject to audit by certified public accountants or auditing firm.

*** Explanation regarding the appropriate use of financial forecast and other information**

1. The forecasts and future projections contained herein have been prepared on the basis of rational decisions given the information available as of the date of announcement of this document. These forecasts do not represent a commitment by the Company, and actual performance may differ substantially from forecasts for a variety of reasons. Please refer to “4) Outlook for future” within “1. Overview of operating performance” on page 4 of the attachment to this document.
2. Supplementary financial materials (in Japanese and English) will be posted on the Sysmex website on Thursday, May 14, 2026.

Content of Supplementary Materials

1. Overview of operating performance	2
1) Operating performance during the year	2
2) Financial conditions at end of the year	3
3) Cash flows during the year	3
4) Outlook for future	4
2. Basic perspective on selection of accounting standards	4
3. Consolidated financial statements and notes	5
1) Consolidated statement of financial position	5
2) Consolidated statement of income	7
3) Consolidated statement of comprehensive income	8
4) Consolidated statement of changes in equity	9
5) Consolidated statement of cash flows	10
6) Notes to the consolidated financial statements	11
1. Notes related to the going concern assumption	11
2. Segment information	11
3. Per-share information	14
4. Significant subsequent event	14

1. Overview of operating performance

1) Operating performance during the year

During the fiscal year under review, the global economy continued to recover moderately overall, although persistently elevated global inflation and uncertainty surrounding U.S. trade policy contributed to a sense of economic uncertainty. In the United States, personal consumption and capital investment remained firm despite the impact of rising prices, while signs of recovery were also observed in Europe. In contrast, domestic demand in China remained sluggish. In addition, worsening conditions in the Middle East caused disruptions in global supply chains for energy resources and other commodities, and uncertainty regarding the outlook for the Japanese and global economies continued.

In the healthcare field, although healthcare cost containment policies expanded in China, medical demand continued to grow, supported by economic growth in emerging countries and global population aging.

Under these circumstances, net sales decreased overall, reflecting significant declines in Japan and China, where the Company was affected by healthcare cost containment policies, despite revenue growth in the Americas and EMEA. On the profit front, profit decreased due to lower net sales, a higher cost of sales ratio, increased selling, general and administrative expenses, and the recording of impairment losses associated with changes in the business environment and revisions to strategy.

Net sales by destination

	Year ended March 31, 2025		Year ended March 31, 2026		YoY (Previous period = 100)
	Amount (Millions of yen)	Percentage of total (%)	Amount (Millions of yen)	Percentage of total (%)	
Japan	67,786	13.3	58,603	11.7	86.5
Americas	131,148	25.8	139,254	27.9	106.2
EMEA (Europe, the Middle East, and Africa)	140,398	27.6	158,034	31.6	112.6
China	117,970	23.2	89,465	17.9	75.8
AP (Asia Pacific)	51,339	10.1	54,649	10.9	106.4
Overseas subtotal	440,857	86.7	441,403	88.3	100.1
Total	508,643	100.0	500,006	100.0	98.3

In Japan, sales of instruments and reagents in the hematology and hemostasis fields decreased. As a result, sales in Japan fell 13.5% year on year, to ¥58,603 million. The domestic sales ratio fell 1.6 percentage point, to 11.7%.

Overseas, sales of reagents in the hemostasis field decreased. However, instruments and reagents sales in the urinalysis and other fields, and reagents in the hematology field increased. Accordingly, overseas sales rose 0.1%, to ¥441,403 million, and the overseas sales ratio increased 1.6 percentage points, to 88.3%.

Selling, general and administrative (SG&A) expenses totaled ¥164,351 million, up 9.0% year on year, due primarily to an increase in personnel associated with business expansion, as well as higher amortization expenses related to investments in digital infrastructure. R&D expenses came to ¥29,162 million, down 7.3%.

As a result, for the fiscal year ended March 31, 2026, the Group recorded consolidated net sales of ¥500,006 million (down 1.7% year on year), operating profit of ¥51,831 million (down 40.8%), profit before tax of ¥49,051 million (down 38.1%), and profit attributable to owners of the parent of ¥35,457 million (down 33.9%).

Performance by segment

(1) Headquarters

In South Korea, hematology instruments grew, but in Japan sales of hematology and hemostasis instruments and reagents decreased. In the medical robotics business, sales of maintenance services grew, but sales of instruments decreased. Consequently, sales fell 6.8% year on year, to ¥87,562 million.

On the profit front, in addition to the decline in sales, a worsening cost of sales ratio and an increase in SG&A expenses led to a segment profit (operating profit) of ¥17,771 million (down 69.9%).

(2) Americas RHQ

In North America, sales rose for hematology instruments and reagents, as well as for urinalysis instruments. In Central and South America, sales of urinalysis instruments and reagents increased. As a result, sales in the Americas were up 6.1% year on year, to ¥130,456 million.

On the profit front, higher sales and other factors pushed up segment profit (operating profit) 26.1% year on year, to ¥8,507 million.

(3) EMEA (Europe, the Middle East, and Africa) RHQ

In the hematology field, sales of reagents grew. Sales of instruments and reagents in the urinalysis and hemostasis fields also increased, mainly in the region's key countries, bolstering sales for the region by 12.1% year on year, to ¥152,110 million.

Although sales grew, SG&A expenses increased in line with business expansion, causing segment profit (operating profit) to fall 6.4% year on year, to ¥9,904 million.

(4) China RHQ

Operating in a difficult business environment affected by policies to curtail medical expenses, we experienced significant sales declines in hematology instruments and reagents, as well as hemostasis reagents. As a result, segment sales were ¥89,269 million, down 24.2% year on year.

Although lower SG&A expenses had a positive impact on profit, lower sales caused segment profit (operating profit) to fall 12.2% year on year, to ¥9,343 million.

(5) Asia Pacific RHQ

In the hematology, hemostasis and urinalysis fields, reagent sales increased. As a result, sales for the region grew 6.1%, to ¥40,581 million.

On the profit front, although the cost of sales ratio deteriorated due to such factors as depreciation associated with the new production site in India completed in August 2024, segment profit (operating profit) rose 3.6%, to ¥3,707 million, reflecting higher sales.

2) Financial conditions at end of the year

As of March 31, 2026, total assets amounted to ¥707,532 million, an increase of ¥42,263 million from the previous fiscal year-end, partly reflecting the depreciation of the yen. This increase was due chiefly to increases of ¥13,802 million in inventories, ¥7,511 million in income taxes receivable, ¥20,185 million in property, plant and equipment, and ¥7,777 million in non-current trade and other receivables, despite a ¥10,066 million decrease in goodwill resulting from the recognition of impairment losses.

Total liabilities increased by ¥1,121 million from March 31, 2025, to ¥201,856 million. While income taxes payable were ¥9,804 million lower, the rise in total liabilities was due mainly to increases in trade and other payables of ¥2,251 million, in contract liabilities of ¥2,671 million, in non-current lease liabilities of ¥6,153 million.

Total equity came to ¥505,676 million, up ¥41,141 million from March 31, 2025. Among principal factors, retained earnings increased ¥13,432 million, and other components of equity increased ¥30,810 million. Equity attributable to owners of the parent to total assets amounted to 71.4% on March 31, 2026, up 1.7 percentage points from 69.7% on March 31, 2025.

3) Cash flows during the year

As of March 31, 2026, cash and cash equivalents amounted to ¥84,117 million, down ¥5,453 million from March 31, 2025.

Cash flows from various activities during the fiscal year are described in more detail below.

(Cash flows from operating activities)

Net cash provided by operating activities was ¥73,848 million, down ¥14,397 million from the previous fiscal year. As principal factors, profit before tax provided ¥49,051 million (down ¥30,170 million from the preceding year), depreciation and amortization provided ¥46,437 million (up ¥7,404 million), impairment loss provided ¥11,557 million (up ¥8,345 million) and income taxes paid used ¥29,720 million (up ¥1,996 million).

(Cash flows from investing activities)

Net cash used in investing activities was ¥51,472 million (down ¥1,016 million). Among major factors, purchases of property, plant and equipment used ¥32,904 million (up ¥3,677 million), purchases of intangible assets used ¥18,065 million (down ¥2,668 million).

(Cash flows from financing activities)

Net cash used in financing activities was ¥37,659 million (up ¥13,337 million). This was mainly due to dividends paid of ¥22,441 million (up ¥4,360 million), and repayments of lease liabilities of ¥11,316 million (up ¥754 million).

4) Outlook for future

Regarding the outlook for the global economy, although conditions are expected to vary by region, a moderate recovery is generally expected to continue. However, downside economic risks are likely to persist, including fluctuations in energy prices and the risk of supply chain fragmentation associated with heightened tensions in the Middle East, as well as developments in the trade policies of major countries and volatility in financial and capital markets.

In the healthcare environment, medical demand is expected to continue growing, supported by economic growth in emerging countries and global population aging. In particular, we anticipate demand growth stemming from improvements in the quality and delivery of healthcare services, including efforts to enhance the safety and productivity of healthcare professionals amid labor shortages, improving healthcare economics, and expanding access to healthcare. In addition, medical DX is likely to accelerate with the spread of artificial intelligence (AI), while the implementation and application of robotic technologies are also projected to expand, unleashing further growth opportunities. In addition, in China, we assume that the policy to curb medical costs will continue to make it difficult to predict.

Under these conditions, the Group launched a new Mid-Term Management Plan covering the period from the fiscal year ending March 31, 2027 through the fiscal year ending March 31, 2029. Under this plan, the Group will focus on the following four priority themes in order to translate its strengths into sustainable growth opportunities:

- Strengthening the competitiveness of the diagnostics business
- Advancing medical DX and data utilization by leveraging the strengths of the diagnostics business
- Improving profitability through value chain transformation
- Redesigning human capital strategy, and financial and capital strategies

Through these initiatives, we aim to improve growth potential, profitability, and capital efficiency, thereby enhancing corporate value.

For the fiscal year ending March 31, 2027, although the profit is expected to decrease due to the decline in sales in China, we forecast consolidated net sales of ¥535,000 million, operating profit of ¥58,000 million, and ROE of 7.2% or higher, driven by solid growth in regions outside China, contributions from the CN™ Series products in the hemostasis field, and the expansion of business in emerging countries.

Note: Our assumptions for annual average exchange rates are USD1 = JPY155.0, EUR1 = JPY180.0, CNY1 = JPY22.0. The forecast outlined above is based on currently available information. Actual performance may differ from this forecast for a variety of reasons.

2. Basic perspective on selection of accounting standards

The Sysmex Group voluntarily adopted IFRS from the fiscal year ended March 31, 2017. Our aim is to increase convenience to shareholders and investors in Japan and overseas by enhancing the international comparability of our financial information in capital markets.

3. Consolidated financial statements and notes

1) Consolidated statement of financial position

(Unit: Millions of yen)

	As of March 31, 2025	As of March 31, 2026
Assets		
Current assets		
Cash and cash equivalents	89,570	84,117
Trade and other receivables	163,007	168,783
Inventories	81,811	95,613
Other short-term financial assets	654	775
Income taxes receivable	1,246	8,757
Other current assets	28,531	30,559
Total current assets	364,821	388,606
Non-current assets		
Property, plant and equipment	130,211	150,396
Goodwill	14,205	4,138
Intangible assets	92,146	93,173
Investments accounted for using the equity method	339	150
Trade and other receivables	26,978	34,756
Other long-term financial assets	12,034	14,025
Asset for retirement benefits	0	0
Other non-current assets	6,880	6,643
Deferred tax assets	17,651	15,641
Total non-current assets	300,447	318,925
Total assets	665,268	707,532

(Unit: Millions of yen)

	As of March 31, 2025	As of March 31, 2026
Liabilities and equity		
Liabilities		
Current liabilities		
Trade and other payables	31,865	34,116
Lease liabilities	9,250	9,555
Other current financial liabilities	1,403	1,316
Income taxes payable	12,784	2,980
Provisions	1,164	1,342
Contract liabilities	18,098	20,770
Accrued expenses	22,355	22,610
Accrued bonuses	14,709	14,976
Other current liabilities	11,194	11,591
Total current liabilities	122,826	119,259
Non-current liabilities		
Long-term loans payable	32,359	31,646
Lease liabilities	23,126	29,280
Other non-current financial liabilities	56	35
Liability for retirement benefits	2,127	2,238
Provisions	1,054	1,307
Other non-current liabilities	11,608	12,198
Deferred tax liabilities	7,575	5,889
Total non-current liabilities	77,908	82,596
Total liabilities	200,734	201,856
Equity		
Equity attributable to owners of the parent		
Capital stock	14,887	14,898
Capital surplus	20,960	21,114
Retained earnings	402,820	416,253
Treasury stock	(12,318)	(15,501)
Other components of equity	37,425	68,236
Total equity attributable to owners of the parent	463,776	505,000
Non-controlling interests	758	675
Total equity	464,534	505,676
Total liabilities and equity	665,268	707,532

2) Consolidated statement of income

(Unit: Millions of yen)

	Year ended March 31, 2025	Year ended March 31, 2026
Net sales	508,643	500,006
Cost of sales	236,665	244,324
Gross profit	271,977	255,681
Selling, general and administrative expenses	150,848	164,351
Research and development expenses	31,455	29,162
Impairment loss	3,211	11,557
Other operating income	2,070	3,659
Other operating expenses	948	2,439
Operating profit	87,583	51,831
Financial income	1,078	865
Financial expenses	3,518	4,359
Share of profit (loss) of associates accounted for using the equity method	(2,071)	(1,364)
Foreign exchange gain (loss)	(3,850)	2,078
Profit before tax	79,221	49,051
Income taxes expenses	25,645	13,676
Profit	53,576	35,374
Profit attributable to		
Owners of the parent	53,669	35,457
Non-controlling interests	(93)	(82)
Profit	53,576	35,374
(Unit: Yen)		
Earnings per share		
Basic	86.07	56.89
Diluted	86.05	56.89

3) Consolidated statement of comprehensive income

(Unit: Millions of yen)

	Year ended March 31, 2025	Year ended March 31, 2026
Profit	53,576	35,374
Other comprehensive income		
Items that will not be reclassified subsequently to profit or loss		
Net gain (loss) on financial assets measured at fair value through other comprehensive income	(2,194)	507
Remeasurements of defined benefit liabilities	(114)	267
Total	(2,308)	774
Items that may be reclassified subsequently to profit or loss		
Exchange differences on translation of foreign operations	(1,830)	30,410
Share of other comprehensive income of investments accounted for using the equity method	(3)	42
Total	(1,833)	30,452
Total other comprehensive income	(4,141)	31,226
Comprehensive income	49,434	66,601
Comprehensive income attributable to		
Owners of the parent	49,527	66,684
Non-controlling interests	(93)	(82)
Comprehensive income	49,434	66,601

4) Consolidated statement of changes in equity
For the year ended March 31, 2025

(Unit: Millions of yen)

	Equity attributable to owners of the parent						Non-controlling interests	Total equity
	Capital stock	Capital surplus	Retained earnings	Treasury stock	Other components of equity	Total		
As of April 1, 2024	14,729	20,830	365,985	(12,315)	42,814	432,045	851	432,897
Profit			53,669			53,669	(93)	53,576
Other comprehensive income					(4,141)	(4,141)		(4,141)
Comprehensive income	—	—	53,669	—	(4,141)	49,527	(93)	49,434
Exercise of warrants	158	90				248		248
Share-based payment transactions		39				39		39
Cash dividends			(18,081)			(18,081)		(18,081)
Purchase of treasury stock				(2)		(2)		(2)
Disposal of treasury stock		0		0		0		0
Transfer to retained earnings			1,247		(1,247)	—		—
Total transactions with the owners	158	129	(16,834)	(2)	(1,247)	(17,796)	—	(17,796)
As of March 31, 2025	14,887	20,960	402,820	(12,318)	37,425	463,776	758	464,534

For the year ended March 31, 2026

(Unit: Millions of yen)

	Equity attributable to owners of the parent						Non-controlling interests	Total equity
	Capital stock	Capital surplus	Retained earnings	Treasury stock	Other components of equity	Total		
As of April 1, 2025	14,887	20,960	402,820	(12,318)	37,425	463,776	758	464,534
Profit			35,457			35,457	(82)	35,374
Other comprehensive income					31,226	31,226		31,226
Comprehensive income	—	—	35,457	—	31,226	66,684	(82)	66,601
Exercise of warrants	10	6				16		16
Share-based payment transactions		170				170		170
Cash dividends			(22,441)			(22,441)		(22,441)
Purchase of treasury stock				(3,214)		(3,214)		(3,214)
Disposal of treasury stock		(22)		31		8		8
Transfer to retained earnings			416		(416)	—		—
Total transactions with the owners	10	153	(22,025)	(3,182)	(416)	(25,459)	—	(25,459)
As of March 31, 2026	14,898	21,114	416,253	(15,501)	68,236	505,000	675	505,676

5) Consolidated statement of cash flows

(Unit: Millions of yen)

	Year ended March 31, 2025	Year ended March 31, 2026
Cash flows from operating activities		
Profit before tax	79,221	49,051
Depreciation and amortization	39,033	46,437
Impairment loss	3,211	11,557
Interest and dividends income	(899)	(812)
Interest expenses	1,949	2,241
Share of loss (profit) of associates accounted for using the equity method	2,071	1,364
Loss on retirement of non-current assets	383	784
Decrease (increase) in trade receivable	(7,150)	6,830
Decrease (increase) in advance payments	706	(713)
Decrease (increase) in inventories	(6,320)	(8,998)
Increase (decrease) in trade payable	162	710
Increase (decrease) in accounts payable—other	(520)	922
Increase (decrease) in contract liabilities	1,720	1,181
Increase (decrease) in accrued expenses	1,113	(1,528)
Decrease/increase in consumption taxes receivable/payable	(1,374)	(2,087)
Increase (decrease) in accrued bonuses	2,118	(201)
Other—net	1,743	(1,578)
Subtotal	117,168	105,161
Interest and dividend received	654	581
Interest paid	(1,853)	(2,173)
Income taxes paid	(27,723)	(29,720)
Net cash provided by (used in) operating activities	88,246	73,848
Cash flows from investing activities		
Purchases of property, plant and equipment	(29,226)	(32,904)
Proceeds from sales of property, plant and equipment	702	1,616
Purchases of intangible assets	(20,733)	(18,065)
Payments resulting in an increase in long-term prepaid expenses	(1,001)	(1,064)
Purchases of investments in equity instruments	(3,821)	(262)
Proceeds from the sale of equity instruments	1,853	525
Purchases of debt instruments	(399)	(1,129)
Payments into time deposits	(1,544)	(1,277)
Proceeds from withdrawal of time deposits	1,777	1,079
Other—net	(95)	9
Net cash provided by (used in) investing activities	(52,488)	(51,472)
Cash flows from financing activities		
Proceeds from long-term loans payable	4,700	—
Repayments of long-term loans payable	(626)	(713)
Exercise of warrants	248	16
Purchase of treasury shares	(2)	(3,214)
Dividends paid	(18,081)	(22,441)
Repayments of lease liabilities	(10,561)	(11,316)
Other—net	2	8
Net cash provided by (used in) financing activities	(24,322)	(37,659)
Effects of exchange rate changes on cash and cash equivalents	2,627	9,830
Net increase (decrease) in cash and cash equivalents	14,062	(5,453)
Cash and cash equivalents at the beginning of the term	75,507	89,570
Cash and cash equivalents at the end of the term	89,570	84,117

6) Notes to the consolidated financial statements

1. Notes related to the going concern assumption

Not applicable

2. Segment information

1) Overview of reportable segments

The reportable segments of the Company and its subsidiaries (the Group) are the constituent business units of the Group for which separate financial data are available and that are examined on a regular basis for the purpose of enabling the Managing Board to allocate managerial resources and evaluate results of operations.

The Group is primarily engaged in the manufacture and sale of diagnostic instruments and reagents. These businesses are conducted in Japan and East Asia by Sysmex and in the Americas, EMEA, China, and the Asia Pacific by regional headquarters established therein. These companies formulate comprehensive strategies tailored to regional characteristics and conduct business activities accordingly. Some overseas subsidiaries are managed by Sysmex depending on the nature of their business.

The five managing company-specific segments are “Headquarters,” “Americas RHQ,” “EMEA RHQ,” “China RHQ,” and “AP RHQ.”

The companies included in these reportable segments are outlined below.

Reportable segments	Companies included in the reportable segments
Headquarters	Sysmex Corporation, Sysmex RA Co., Ltd., 13 other domestic subsidiaries, Oxford Gene Technology IP Limited, Sysmex Partec GmbH, Sysmex Korea Co., Ltd., 11 other overseas subsidiaries
Americas RHQ	Sysmex America, Inc., Sysmex Reagents America, Inc., Sysmex do Brasil Industria e Comercio Ltda., five other subsidiaries in the Americas
EMEA RHQ	Sysmex Europe SE, Sysmex Deutschland GmbH, Sysmex UK Limited, Sysmex France S.A.S., 25 other subsidiaries in the EMEA region
China RHQ	Sysmex Shanghai Ltd., Jinan Sysmex Medical Electronics Co., Ltd., two other subsidiaries in China
AP RHQ	Sysmex Asia Pacific Pte Ltd., Sysmex India Pvt. Ltd., nine other subsidiaries in the Asia Pacific region

2) Segment profit and operating results

Profit and operating results from continuing operations by reportable segment of the Group are as follows;

Intersegment sales are determined based on market prices or costs of goods manufactured.

Accounting policies of reporting segments are consistent with the Group’s accounting policies indicated in the consolidated financial statements for the previous fiscal year.

For the year ended March 31, 2025

(Unit: Millions of yen)

	Reportable segment						Adjustments (Note 1)	Consolidated (Note 2)
	Head- quarters	Americas RHQ	EMEA RHQ	China RHQ	AP RHQ	Total		
Sales								
Sales to external customers	93,988	122,916	135,671	117,828	38,239	508,643	—	508,643
Intersegment sales	161,269	30	604	489	50	162,444	(162,444)	—
Total	255,258	122,946	136,276	118,317	38,289	671,088	(162,444)	508,643
Segment profit	59,104	6,743	10,583	10,646	3,579	90,657	(3,073)	87,583
Financial income	—	—	—	—	—	—	—	1,078
Financial expenses	—	—	—	—	—	—	—	3,518
Share of profit (loss) on equity method	—	—	—	—	—	—	—	(2,071)
Foreign exchange gain (loss)	—	—	—	—	—	—	—	(3,850)
Profit before tax	—	—	—	—	—	—	—	79,221
Income tax expenses	—	—	—	—	—	—	—	25,645
Profit	—	—	—	—	—	—	—	53,576
Other								
Depreciation and amortization (Note 3)	22,120	6,024	6,305	1,142	4,388	39,981	(948)	39,033
Impairment loss	3,207	—	—	—	3	3,211	—	3,211

Notes:

1. Segment profit adjustments of negative ¥3,073 million include negative ¥2,409 million for the unrealized gains on inventories, and negative ¥663 million for the unrealized gains on non-current assets.
2. Segment profit is reconciled with operating profit in the consolidated statement of income.
3. The negative ¥948 million reconciliation in depreciation and amortization is an adjustment related to intersegment transactions.

For the year ended March 31, 2026

(Unit: Millions of yen)

	Reportable segment						Adjustments (Note 1)	Consolidated (Note 2)
	Head- quarters	Americas RHQ	EMEA RHQ	China RHQ	AP RHQ	Total		
Sales								
Sales to external customers	87,562	130,456	152,110	89,296	40,581	500,006	—	500,006
Intersegment sales	130,449	25	786	323	50	131,635	(131,635)	—
Total	218,011	130,482	152,896	89,619	40,631	631,641	(131,635)	500,006
Segment profit	17,771	8,507	9,904	9,343	3,707	49,232	2,598	51,831
Financial income	—	—	—	—	—	—	—	865
Financial expenses	—	—	—	—	—	—	—	4,359
Share of profit (loss) on equity method	—	—	—	—	—	—	—	(1,364)
Foreign exchange gain (loss)	—	—	—	—	—	—	—	2,078
Profit before tax	—	—	—	—	—	—	—	49,051
Income tax expenses	—	—	—	—	—	—	—	13,676
Profit	—	—	—	—	—	—	—	35,374
Other								
Depreciation and amortization (Note 3)	26,566	7,176	7,927	1,029	4,845	47,545	(1,107)	46,437
Impairment loss	11,519	—	—	—	37	11,557	—	11,557

Notes:

1. Segment profit adjustments of ¥2,598 million include ¥2,353 million for the unrealized gains on inventories, and ¥245 million for the unrealized gains on non-current assets.
2. Segment profit is reconciled with operating profit in the consolidated statement of income.
3. The negative ¥1,107 million reconciliation in depreciation and amortization is an adjustment related to intersegment transactions.

3. Per-share information

The basis for calculating basic profit per share and diluted profit per share is as follows.

	Year ended March 31, 2025	Year ended March 31, 2026
Basis for calculating basic earnings per share		
Profit attributable to owners of parent (Millions of yen)	53,669	35,457
Profit not attributable to common stock shareholders of the parent (Millions of yen)	—	—
Profit used in calculating basic earnings per share (Millions of yen)	53,669	35,457
Average number of common stock shares during the period (Thousands of shares)	623,531	623,213
Basis for calculating diluted earnings per share		
Profit used in calculating basic earnings per share (Millions of yen)	53,669	35,457
Profit adjustment (Millions of yen)	—	—
Profit used in calculating diluted earnings per share (Millions of yen)	53,669	35,457
Average number of common stock shares during the period (Thousands of shares)	623,531	623,213
Effect of dilutive shares (Thousands of shares)	194	—
Average number of common stock shares after adjustment for dilution (Thousands of shares)	623,726	623,213

Notes:

1. The Company has introduced the Executive Compensation BIP Trust and the ESOP Trust. In the calculation of basic earnings per share and diluted earnings per share, the Company's shares held by these trusts are included in treasury stock and are excluded from calculations of the Company's own shares and average number of shares during the period.
2. Diluted earnings per share are the same as basic earnings per share, as there are potential shares outstanding but they do not have a dilutive effect.

4. Significant subsequent event

(Acquisition of medical equipment business of JEOL Ltd.)

Sysmex resolved to acquire the medical equipment business (the “Target Business”) of JEOL Ltd. “JEOL”) and entered into a share transfer agreement with JEOL on September 2, 2025. Under this agreement, JEOL established a new company, K.K. Medical Equipment Business Split Preparation Company (the “Target Company”), which assumed the Target Business through an absorption-type company split. On April 1, 2026, Sysmex acquired all the Target Company's shares.

1) Overview of the acquired company

Name: K.K. Medical Equipment Business Split Preparation Company

Business description: Manufacture, sales, and research and development of medical instruments; consigned processing of related products and components; maintenance and services; and procurement and sales of peripheral equipment.

2) Overview of the business combination

By taking over the Target Business, comprising manufacturing, sales, development and research, and other operations related to JEOL's clinical chemistry analyzer*1, BioMajesty™*2, Sysmex aims to incorporate a highly competitive product lineup in the field of clinical chemistry into the Group's product portfolio, strengthen collaborative relationships with reagent manufacturers, and expand business development, including in overseas markets.

In addition, due to the acquisition of shares, the Target Company changed its trade name to Sysmex BioMajesty Corporation.

*1 Clinical Chemistry Analyzer:

An analyzer that utilizes bodily fluids, such as blood and urine, as specimens to measure various components, including glucose, cholesterol, proteins, and enzymes. In addition to general clinical chemistry parameters, such devices are now capable of measuring a broad range of tests, including immunoassays, tumor markers, and selected hemostasis-related parameters.

*2 BioMajesty Series:

This series of clinical chemistry analyzers employ a unique sample dilution method, enabling the use of minimal sample and reagent volumes. The extensive lineup ranges from the high-end JCA-BM8000 series, designed for high-speed, large-volume processing, to the low-end JCA-BM6010G, a space-saving model that combines multifunctionality and ease of use, meeting the diverse needs of testing laboratories.

3) Acquisition date

April 1, 2026

4) Consideration for the acquisition

It is being calculated using the method specified in the Share Purchase Agreement.

5) Fair value of assets acquired and liabilities assumed as of the acquisition date

Currently being determined

(Borrowing of substantial funds)

The Company took out the following loans on April 28, 2026. The details are as follows:

1) Reason for the loans

Sysmex took out the loans to address increased funding needs associated with the expansion of the Group's business, including operations in Central and South America, as well as the enhancement of shareholder returns, including the acquisition of treasury stock.

2) Overview of the loans

1. Lenders: Multiple banks
2. Total borrowing amount: ¥50,000 million
3. Interest rate: Fixed interest rate
4. Borrowing period: Five years
5. Collateral: Unsecured